Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

BIOPORTO A/S (BIOPOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
3.215(c) 3.175(c) 3.22(c) 3.27(c) 3.24(c) Last
63 490 83 456 148 027 89 395 164 970 Volume
+0.47% -1.24% +1.42% +1.55% -0.92% Change
More quotes
Company
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings.Its products specialize in coagulation, immunodeficiencies, diabetes, peptide hormones, and kidney diseases.Its portfolio consists of NGAL Test, NGAL ELISA kits,... 
Sector
Pharmaceuticals
Calendar
05/03Earnings Release
More about the company
Latest news on BIOPORTO A/S
04/19BAVARIAN NORDIC A/S : BioPorto appoints Ole Larsen as CFO
AQ
04/18BIOPORTO A/S : appoints Ole Larsen as CFO
AQ
04/13BIOPORTO A/S : - Annual General Meeting
AQ
04/03BIOPORTO A/S : receives intention to grant for a divisional NGAL cutoff patent i..
AQ
03/21BIOPORTO A/S : Notice Convening the Annual General Meeting
AQ
03/08BIOPORTO A/S : Execution, Growth and Increased Awareness
AQ
03/07BIOPORTO A/S : finalizes enrolment of patients for The NGAL Test clinical study ..
AQ
03/06BIOPORTO A/S : finalizes enrolment of patients for The NGAL Test™ clinical..
AQ
02/10BIOPORTO A/S : and Roche Diagnostics sign a distribution agreement for NGAL
AQ
02/09BIOPORTO A/S : and Roche Diagnostics sign a distribution agreement for NGAL
AQ
More news
Sector news : Diagnostic & Testing Substances Manufacturers
04/21TAKEDA PHARMACEUTICAL : Keeps Courting Shire -- WSJ
DJ
04/20GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20SHIRE PLC SHIRE PLC : Statement Re Proposal From -2-
DJ
04/20SHIRE PLC SHIRE PLC : Statement Re Proposal From Takeda Pharmaceutical Company L..
DJ
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
2017BioPorto A/S : Private placement fully subscribed  
2017BioPorto Release: First Patient Recruited For The NGAL Test Clinical Study In.. 
2017BioPorto A/S : First patient recruited for The NGAL Test™ clinical .. 
2017BioPorto A/S: BioPorto completes pre-submission discussions with the FDA #Fin.. 
2016BioPorto A/S: BioPorto expands its NGAL related patent portfolio #Finanzierun.. 
More tweets
Qtime:31
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Managers
NameTitle
Peter Mørch Eriksen Chief Executive Officer
Thomas Magnussen Chairman
Jan Kuhlmann Andersen Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S-2.11%0
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571